X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cabozantinib (148) 148
index medicus (111) 111
oncology (88) 88
humans (81) 81
metastasis (52) 52
cancer (47) 47
angiogenesis (45) 45
c-met (42) 42
met (40) 40
xl184 (36) 36
pharmacology & pharmacy (34) 34
thyroid cancer (34) 34
male (32) 32
sorafenib (32) 32
care and treatment (30) 30
inhibitor (29) 29
pyridines - therapeutic use (29) 29
anilides - therapeutic use (28) 28
antineoplastic agents - therapeutic use (27) 27
female (27) 27
animals (25) 25
double-blind (25) 25
expression (25) 25
vascular endothelial growth factor (25) 25
analysis (24) 24
renal cell carcinoma (24) 24
cancer therapies (23) 23
middle aged (23) 23
review (23) 23
carcinoma (22) 22
clinical trials (22) 22
hepatocellular carcinoma (22) 22
medicine & public health (22) 22
protein kinase inhibitors - therapeutic use (22) 22
research (22) 22
sunitinib (22) 22
tumors (22) 22
tyrosine (22) 22
open-label (21) 21
pyridines - administration & dosage (21) 21
targeted therapy (21) 21
vandetanib (21) 21
endothelial growth-factor (20) 20
tyrosine kinase inhibitor (20) 20
anilides - administration & dosage (19) 19
chemotherapy (19) 19
kinases (19) 19
medullary-thyroid cancer (19) 19
pyridines - pharmacology (19) 19
aged (18) 18
anilides - pharmacology (18) 18
cabozantinib xl184 (18) 18
everolimus (18) 18
pharmacokinetics (18) 18
phase-ii (18) 18
prostate cancer (18) 18
ret (18) 18
therapy (18) 18
thyroid neoplasms - drug therapy (18) 18
treatment outcome (18) 18
adult (17) 17
drug therapy (17) 17
medical prognosis (17) 17
growth (16) 16
health aspects (15) 15
thyroid neoplasms - pathology (15) 15
antineoplastic agents - adverse effects (14) 14
immunotherapy (14) 14
kidney cancer (14) 14
neoplasms. tumors. oncology. including cancer and carcinogens (14) 14
patients (14) 14
pyridines - adverse effects (14) 14
anilides - adverse effects (13) 13
antineoplastic agents - pharmacology (13) 13
carcinoma, renal cell (13) 13
growth-factor (13) 13
liver cancer (13) 13
metastases (13) 13
proto-oncogene proteins c-met - antagonists & inhibitors (13) 13
survival (13) 13
tumor-growth (13) 13
article (12) 12
cancer research (12) 12
medullary thyroid cancer (12) 12
mutation (12) 12
mutations (12) 12
pharmacology/toxicology (12) 12
phase-ii trial (12) 12
protein kinase inhibitors - pharmacology (12) 12
tyrosine kinase (12) 12
tyrosine kinase inhibitors (12) 12
vegf (12) 12
vegfr2 (12) 12
anilides - pharmacokinetics (11) 11
antineoplastic agents - administration & dosage (11) 11
carcinoma, renal cell - drug therapy (11) 11
disease-free survival (11) 11
fda approval (11) 11
inhibitors (11) 11
kidney neoplasms - drug therapy (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Future Oncology, ISSN 1479-6694, 08/2013, Volume 9, Issue 8, pp. 1083 - 1092
Cabozantinib (XL184) is an oral multiple receptor tyrosine kinase inhibitor manufactured by Exelixis Inc., CA, USA. It mainly inhibits three tyrosine kinase... 
advanced medullary thyroid cancer | XL184 | tyrosine kinase inhibitor | BMS-907351 | cabozantinib | RET | FOLLOW-UP | PREVALENCE | CHEMOTHERAPY | ONCOLOGY | RAS MUTATIONS | INHIBITOR | CARCINOMA | EXPRESSION | MET | ENDOTHELIAL GROWTH-FACTOR
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 05/2017, Volume 79, Issue 5, pp. 923 - 932
Journal Article
Urology, ISSN 0090-4295, 03/2017, Volume 101, pp. 169.e7 - 169.e13
Journal Article
Molecular cancer research : MCR, ISSN 1541-7786, 02/2019, Volume 17, Issue 2, pp. 499 - 507
Osimertinib (AZD9291) has an efficacy superior to that of standard EGFR-tyrosine kinase inhibitors for the first-line treatment of patients with EGFR-mutant... 
THERAPY | CABOZANTINIB XL184 | ONCOLOGY | STATISTICS | MUTATION | OPEN-LABEL | PATIENT | INHIBITORS | MET | RECEPTOR TYROSINE KINASE | AZD9291 | CELL BIOLOGY
Journal Article
Oncogene, ISSN 0950-9232, 05/2016, Volume 35, Issue 21, pp. 2687 - 2697
Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the... 
ACTIVATION | METASTASIS | ANGIOGENESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER | CELL BIOLOGY | RECEPTOR TYROSINE KINASES | CABOZANTINIB XL184 | ONCOLOGY | C-MET | GROWTH | GENETICS & HEREDITY | EXPRESSION | PROGRESSION | Proto-Oncogene Proteins c-met - metabolism | Humans | Drug Resistance, Neoplasm | Molecular Targeted Therapy | Sunitinib | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Carcinoma, Renal Cell - enzymology | Indoles - pharmacology | Carcinoma, Renal Cell - drug therapy | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Carcinoma, Renal Cell - pathology | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Proto-Oncogene Proteins - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Pyrroles - pharmacology | Animals | Receptor Protein-Tyrosine Kinases - genetics | Mice, Nude | Kidney Neoplasms - enzymology | Kidney Neoplasms - pathology | Cell Proliferation - drug effects | Mice | Kidney Neoplasms - drug therapy | Molecular targeted therapy | Genetic aspects | Carcinoma, Renal cell | Drug therapy | Drug resistance | Properties | Phosphotransferases | Methods | Cancer therapies | Kidney cancer | Metastasis | Cabozantinib | Renal Cell Carcinoma | AXL | MET
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 50, pp. 87891 - 87902
The tumor microenvironment (TME) is increasingly recognized as the arbiter of metastatic progression and drug resistance in advanced prostate cancer (PCa).... 
Cabozantinib | Carcinoma associated fibroblasts | Metastasis | Prostate cancer | CELLS | XL184 | SUPPRESSION | CANCER | cabozantinib | CELL BIOLOGY | BRAF INHIBITION | prostate cancer | metastasis | GROWTH | carcinoma associated fibroblasts | BONE | MET
Journal Article
Cancer Research, ISSN 0008-5472, 07/2011, Volume 71, Issue 14, pp. 4758 - 4768
Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling slow the growth of many types of tumors, but eventually the disease progresses. Multiple... 
BREAST-CANCER | INVASIVE GROWTH | METASTASIS | ONCOLOGY | TYROSINE KINASE | IN-VIVO | THERAPEUTIC TARGET | TUMOR-GROWTH | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | SMALL-MOLECULE INHIBITOR | Proto-Oncogene Proteins c-met - metabolism | Basement Membrane - drug effects | Vascular Endothelial Growth Factor Receptor-3 - biosynthesis | Adenoma, Islet Cell - pathology | Apoptosis - drug effects | Pancreatic Neoplasms - blood supply | Adenoma, Islet Cell - blood supply | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Basement Membrane - pathology | Quinolines - pharmacology | Neovascularization, Pathologic - pathology | Pancreatic Neoplasms - drug therapy | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Adenoma, Islet Cell - drug therapy | Vascular Endothelial Growth Factor Receptor-2 - biosynthesis | Cell Hypoxia - drug effects | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Mice, Inbred C57BL | Pancreatic Neoplasms - pathology | Basement Membrane - metabolism | Animals | Neovascularization, Pathologic - drug therapy | Anilides - pharmacology | Mice | Neovascularization, Pathologic - metabolism | Pyridines - pharmacology | Vascular Endothelial Growth Factor Receptor-3 - antagonists & inhibitors | RIP-Tag2 mice | receptor tyrosine kinases | VEGF | XL184 (cabozantinib) | c-Met | Angiogenesis inhibitors | XL999 | XL880 (foretinib, GSK1363089)
Journal Article
WORLD JOURNAL OF GASTROENTEROLOGY, ISSN 1007-9327, 08/2019, Volume 25, Issue 29, pp. 3870 - 3896
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Journal Article